

NOTICE OF THE 7TH EXTRAORDINARY GENERAL MEETING

Notice is hereby given to members that the 7th Extraordinary General Meeting (EGM) of Navana Pharmaceuticals PLC. will be held on Tuesday, May 07, 2024 at 12:30 PM hybrid system at LAVITA Hall, Lakeshore Hotels (Gulshan), at House-46, Road-41, Gulshan, Dhaka-1212 also using digital platform through the link https://navanaphar.digitalegmbd.net to transact the following businesses:

AGENDA

Agenda 01: Decision on change in the Use of Proceeds of IPO Partially & Extend the time of full utilization of Initial Public Offering (IPO) Proceeds:

"**Resolved that** the proposal to change the Use of Proceeds of IPO fund, whereas an amount of **BDT 13.12 crore** was earmarked for Modernization and Expansion of SVPO Facility. Now the Board has decided to use the fund in the construction of new Generic Production Unit. The company has already completed 71.31% of total IPO proceeds of BDT 75 crore.

SI. No	Existing approved IPO use of Proceeds	Amount (Tk.)	SI. No	Revised (Recommended) IPO use of Proceeds	Amount (Tk.)	Sources of finance
01	Modernization and Expansion of SVPO Facility	131,185,000	01	construction of new Generic Production unit	131,185,000	To be used from IPO proceeds
					1,321,549,375	To be financed from company's Internal & External Sources
Total		131,185,000	Total		1,452,734,375	

The details of the recommended revised use of proceed of IPO are as follows:

"Further Resolved that the proposal to extend the time of full utilization of Initial Public Offering (IPO) proceeds within 36 months after receiving IPO proceeds to accommodate the proposed changes in Use of IPO Proceeds."

By order of the Board

Dated: April 04, 2024



LORENS SHAMOL MOLLICK FCS Company Secretary

Factory: Rupshi, Narayanganj, Tel: +8801713193939, E-mail: admin_plant@navanapharma.com

www.navanapharma.com



Notes:

- (1) The 'Record Date' in lieu of Book Closure was fixed on Tuesday, **02 April, 2024**.
- (2) The shareholders whose name appeared in the Depository Register (CDBL) or register of the member of the company on the "Record Date" **i.e. Tuesday**, **02 April, 2024** will be entitled to attend in the Extraordinary General Meeting.
- (3) A member, eligible to attend & vote the EGM, may appoint a proxy for Individual & Authorization for institution to attend and vote on his/her/ institutional shareholder of behalf. The instrument appointing Proxy (to be duly signed and affixed by the members with a revenue stamp of Tk. 20) / Authorization must be submitted to the Share Office of the company at least 48 hours before EGM. Members may download Proxy Form from the Company's website (i.e. www.navanapharma.com).
- (4) Link for joining EGM through Digital Platform is https://navanaphar.digitalegmbd.net The Details procedures to participate in the hybrid meeting have provided in the company's website at www.navanapharma.com, Investor's Relationship Dept. as well as the link and address of EGM venue has already e-mailed to the respective members e-mail address which is available in the Depository Register as per record date. Members can join the hybrid Extraordinary General Meeting using their laptop, PC, Mobile, or Tab providing their respective Name, 16-Digit BO ID/folio number, and No. of Shares and vote shall be conduct through digital ballot system.
- (5) The members will be able to submit their questions/comments and vote electronically 48 hours before commencement of the EGM and during the EGM.
- (6) In Compliance with BSEC Notification No. BSEC/CMRRCD/2006-158/208/Admin/81 dated 20 June 2018 Proxy Form along with the Notice sent in soft Form to the Members' registered e-mail address linked with their respective BO ID as on record date.
- (7) No gift or benefit in cash or kind shall be paid / offered to the shareholders as per circular No. SEC/CMRRCD/2009-193/154 dated 24 October 2013 of BSEC for attending the EGM.

Factory: Rupshi, Narayanganj, Tel: +8801713193939, E-mail: admin_plant@navanapharma.com